Irene Flores' advocacy for bedside nurses helped build a local stem cell transplant program, making her an Extraordinary Healer Award nominee.
|Articles|August 15, 2007
- Fall 2007
- Volume 6
- Issue 5
Planning for Future Care
Internet resources to help cancer survivors with follow-up care after cancer treatment.
Advertisement
A number of resources can help survivors plan for the future:
>
"Coming Together to Improve Care for Survivors of Adult Cancer, The Master Action Plan from the November 2006 Stakeholders' Meeting in Washington, D.C." and other resources can be found at
>
"From Cancer Patient to Cancer Survivor: Lost in Transition" can be ordered, or downloaded and read free at
>
The American Cancer Society's Cancer Survivor Network has information on communicating with your doctor as well as other survivor information at
>
The Lance Armstrong Foundation offers survivorshop worksheets and a survivors' notebook at
>
The National Cancer Insititute booklet "Facing Forward: Life After Cancer Treatment" can be found at
>
The Cancer Survivors Project has guidelines for survivors, including information on obtaining a treatment summary, organized by type of cancer, at
Articles in this issue
almost 17 years ago
More About Painalmost 17 years ago
The Problem with Pain Centersabout 19 years ago
Beneficial Riskabout 19 years ago
The New Sarcoma Storyabout 19 years ago
The HRT Connectionabout 19 years ago
In Search of Quality Mammographyabout 19 years ago
Powers of Predictionabout 19 years ago
Progress in Treating Multiple Myelomaabout 19 years ago
Use As Directedabout 19 years ago
All in the FamilyAdvertisement
Related to this article
Lunsumio added to Revlimid kept relapsed or refractory follicular lymphoma from worsening longer than Rituxan plus Revlimid in the phase 3 CELESTIMO trial.
Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung cancer, offering fresh options.
See 5 years of FDA leukemia approvals for CLL, AML and CML — new drugs, new drug classes, and how many patients they've actually helped.
Phase 2 findings on divesiran point to a potential way to control hematocrit while reducing repeated blood draws for those living with polycythemia vera, like Nona Baker.
Four of seven patients had no visible cancer on scans in early data from CONVERGE, a trial testing a tumor injection meant to boost radiation in lung cancer.
FDA approves Inluriyo plus Verzenio for adults with ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
September is Blood Cancer Awareness Month, and the pipeline for leukemia, lymphoma and myeloma is as active as it has been in years.
Advertisement
Advertisement